Greer Laboratories   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Lenoir NC United States (1904)
Status: Acquired by Stallergenes (2015)

Organization Overview

First Clinical Trial
2008
NCT00599872
First Marketed Drug
1930
timothy grass pollen allergen extract (Grastek)
First NDA Approval
1994
plague vaccine
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Greer Laboratories, Inc. | Woodmont Pharmaceuticals, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Conjunctivitis (Phase 1)

Conjunctivitis, Allergic (Phase 1)

Hypersensitivity (Phase 2)

Milk Hypersensitivity (Phase 2)

Rhinitis (Phase 3)

Rhinitis, Allergic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 3